167 related articles for article (PubMed ID: 15563239)
1. Omeprazole/Antacid-powder suspension-Santarus: omeprazole/sodium bicarbonate powder-Santarus, SAN 05.
Drugs R D; 2004; 5(6):349-50. PubMed ID: 15563239
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole/antacid-powder suspension--Santarus: Acitrel, Rapinex Powder for oral suspension, SAN 05.
Drugs R D; 2004; 5(4):234-5. PubMed ID: 15230632
[TBL] [Abstract][Full Text] [Related]
3. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders.
Castell D
Expert Opin Pharmacother; 2005 Nov; 6(14):2501-10. PubMed ID: 16259581
[TBL] [Abstract][Full Text] [Related]
4. Zegerid--immediate-release omeprazole.
Med Lett Drugs Ther; 2005 Apr; 47(1206):29. PubMed ID: 15821632
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients.
Conrad SA; Gabrielli A; Margolis B; Quartin A; Hata JS; Frank WO; Bagin RG; Rock JA; Hepburn B; Laine L
Crit Care Med; 2005 Apr; 33(4):760-5. PubMed ID: 15818102
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
7. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
Howden CW
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
[TBL] [Abstract][Full Text] [Related]
8. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use.
Burnett JE; Balkin ER
Am J Health Syst Pharm; 2006 Nov; 63(22):2240-7. PubMed ID: 17090745
[TBL] [Abstract][Full Text] [Related]
9. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.
Sharma VK; Peyton B; Spears T; Raufman JP; Howden CW
Aliment Pharmacol Ther; 2000 Jul; 14(7):887-92. PubMed ID: 10886044
[TBL] [Abstract][Full Text] [Related]
10. BUDGET IMPACT ANALYSIS OF USING OMEPRAZOLE IMMEDIATE-RELEASE ORAL SUSPENSION IN REPLACE OF INTRAVENOUS PANTOPRAZOLE IN CRITICALLY ILL PATIENTS.
Foroutan N; Fahimi F; Dabiri Y; Foroutan A; Habibi M; Salamzadeh J
J Popul Ther Clin Pharmacol; 2015 Dec; 22(3):e292-e302. PubMed ID: 28414416
[TBL] [Abstract][Full Text] [Related]
11. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension.
Johnson CE; Cober MP; Ludwig JL
Ann Pharmacother; 2007 Dec; 41(12):1954-61. PubMed ID: 17956960
[TBL] [Abstract][Full Text] [Related]
12. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
14. Comparison of paste and suspension formulations of omeprazole in the healing of gastric ulcers in racehorses in active training.
Nieto JE; Spier S; Pipers FS; Stanley S; Aleman MR; Smith DC; Snyder JR
J Am Vet Med Assoc; 2002 Oct; 221(8):1139-43. PubMed ID: 12387383
[TBL] [Abstract][Full Text] [Related]
15. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
16. Review article: prevention of stress-related mucosal bleeding with proton-pump inhibitors.
Maton PN
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():45-52. PubMed ID: 16303037
[TBL] [Abstract][Full Text] [Related]
17. [Gastric acid suppression of a new oral powder omeprazole suspension for infants with gastroesophageal reflux disease. A pilot study].
Orsi M; Donato G; Busoni V; Naisberg G; Caruso N
Acta Gastroenterol Latinoam; 2011 Jun; 41(2):111-8. PubMed ID: 21894724
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole and lansoprazole suspensions for nasogastric administration.
McAndrews KL; Eastham JH
Am J Health Syst Pharm; 1999 Jan; 56(1):81. PubMed ID: 10048885
[No Abstract] [Full Text] [Related]
19. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacy compounding of an omeprazole suspension].
Van Der Straeten F; Al-Afandi A; De Paepe K; Bovy J; Plaizier-Vercammen J
J Pharm Belg; 2009 Jun; (2):54-63. PubMed ID: 19739529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
